FLT3 and acute myeloid leukemia: Besides, IDH1 inhibitor ivosidenib [101] and IDH2 inhibitor enasidenib [102,103], both approved by the FDA, are active against IDH1/2-mutant relapsed/refractory AML, though the significance of co-existing FLT3 mutations is not fully understood.